

Tanios S Bekaii-Saab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9409100/publications.pdf>

Version: 2024-02-01

121
papers

3,056
citations

201385

27
h-index

174990

52
g-index

132
all docs

132
docs citations

132
times ranked

4815
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Suboptimal Response to Immune Checkpoint Inhibitors. <i>Advanced Biology</i> , 2023, 7, e2101319.	1.4	5
2	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
3	Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6
4	Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. <i>Cancer Prevention Research</i> , 2022, 15, 121-128.	0.7	9
5	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
6	REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS213-TPS213.	0.8	0
7	KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS^{G12C} mutation.. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-519.	0.8	60
8	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS366-TPS366.	0.8	2
9	A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 563-563.	0.8	0
10	A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic <i>KRAS/NRAS</i> mutant (mut) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 116-116.	0.8	2
11	A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 100-100.	0.8	3
12	Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 93-93.	0.8	1
13	SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterationsâ€”Biliary tract cancer cohort.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS489-TPS489.	0.8	0
14	MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinomaâ€”Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS371-TPS371.	0.8	7
15	Acquired Immunotherapy Resistance in Gastrointestinal Cancers. <i>JAMA Network Open</i> , 2022, 5, e224646.	2.8	1
16	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2022, 8, 760.	3.4	35
17	Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	1.4	13
18	<i>BRAF</i>-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	0.8	21

#	ARTICLE	IF	CITATIONS
19	Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 3571-3571.	0.8	0
20	Universal genetic testing versus guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community oncology program.. Journal of Clinical Oncology, 2022, 40, 10588-10588.	0.8	0
21	KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities.. Journal of Clinical Oncology, 2022, 40, 4130-4130.	0.8	0
22	ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).. Journal of Clinical Oncology, 2022, 40, TPS4170-TPS4170.	0.8	0
23	Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.. Journal of Clinical Oncology, 2022, 40, 4086-4086.	0.8	0
24	IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).. Journal of Clinical Oncology, 2022, 40, e21134-e21134.	0.8	1
25	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precision Oncology, 2022, , .	1.5	11
26	ELU-FR1±-1: A study to evaluate ELU001 in patients with solid tumors that overexpress folate receptor alpha (FR1±).. Journal of Clinical Oncology, 2022, 40, TPS3158-TPS3158.	0.8	2
27	Co-occurring alterations across molecular pathways in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 3590-3590.	0.8	0
28	Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series.. Journal of Clinical Oncology, 2022, 40, 4145-4145.	0.8	1
29	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. JAMA Oncology, 2022, 8, 1257.	3.4	6
30	Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. Pancreatology, 2021, 21, 379-383.	0.5	5
31	MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).. Journal of Clinical Oncology, 2021, 39, TPS153-TPS153.	0.8	24
32	Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).. Journal of Clinical Oncology, 2021, 39, TPS149-TPS149.	0.8	2
33	PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, TPS143-TPS143.	0.8	5
34	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 3641-3648.	3.2	32
35	Circulating cell free tumor DNA detection as a prognostic tool in advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 4130-4130.	0.8	0
36	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in Liver Disease, 2021, 41, 136-141.	1.8	10

#	ARTICLE	IF	CITATIONS
37	<i>IDH1</i> and <i>IDH2</i> Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4009.	0.8	11
38	Clinical impact of pathogenic germline variants in pancreatic cancer: Results from a multicenter prospective universal genetic testing study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4118-4118.	0.8	0
39	Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population-Based Analysis. <i>Oncologist</i> , 2021, 26, 733-739.	1.9	12
40	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data—Reply. <i>JAMA Oncology</i> , 2021, 7, 941.	3.4	0
41	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	1.5	2
42	The role of microbiome in pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 777-789.	2.7	27
43	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205
44	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 348-348.	0.8	0
45	Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN G14-198).. <i>Journal of Clinical Oncology</i> , 2021, 39, 413-413.	0.8	3
46	Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients may predict therapeutic outcome.. <i>Journal of Clinical Oncology</i> , 2021, 39, 423-423.	0.8	2
47	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252.	0.8	16
48	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	1.3	17
49	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	1.3	8
50	Transitioning from second-line to third-line therapy in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 3, 1-20.	0.3	0
51	Proactive transitioning to third-line treatment in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 3, 5-7.	0.3	0
52	Q&A: colorectal cancer in younger patients. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 3, 15-17.	0.3	0
53	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
54	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17

#	ARTICLE	IF	CITATIONS
55	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1681-e1690.	1.9	5
56	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
57	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	1.4	16
58	Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 586-590.	0.6	5
59	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. <i>Onc Immunology</i> , 2020, 9, 1818437.	2.1	20
60	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	0.5	12
61	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	2.2	33
62	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	0.5	26
63	The Role of Maintenance Therapy in Metastatic Colorectal Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 937.	3.4	1
64	Cases in the management of metastatic colorectal cancer: sequencing therapies in a patient with the V600E mutation. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18 Suppl 19, 1-8.	0.3	0
65	AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing <i>FGFR2</i> fusions. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, AB051-AB051.	0.7	18
66	Sister Mary Joseph Nodule in Advanced Pancreatic Adenocarcinoma Identified on 18F-FDG PET/MRI. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 341-342.	0.4	3
67	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	3.2	43
68	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	3.2	40
69	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	0.5	24
70	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4087-4087.	0.8	42
71	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. <i>Chinese Clinical Oncology</i> , 2019, 8, S19-S19.	0.4	1
72	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	1.1	22

#	ARTICLE	IF	CITATIONS
73	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018, 37, 3440-3455.	2.6	37
74	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	1.9	63
75	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	2.3	7
76	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
77	Phase II Study of BGJ398 in Patients With <i>FGFR</i> -Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
78	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1063-1073.	0.6	9
79	Novel immunotherapy strategies for hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	1.0	6
80	Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. <i>Investigational New Drugs</i> , 2018, 36, 1037-1043.	1.2	23
81	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	1.7	16
82	Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 7, 16-18.	0.3	0
83	A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 17, 5-7.	0.3	0
84	New guideline-sanctioned and emerging interventions for pancreatic cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16 Suppl 17, 7-9.	0.3	0
85	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	2.9	73
86	Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 485-498.	1.5	4
87	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. <i>Cancer Research</i> , 2017, 77, 2647-2660.	0.4	113
88	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017, 8, 14755.	5.8	96
89	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	1.9	131
90	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 344-356.	1.9	31

#	ARTICLE	IF	CITATIONS
91	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2017, 16, e119-e122.	1.0	14
92	Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. <i>Diagnostics</i> , 2017, 7, 50.	1.3	10
93	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017, 5, 10.	1.4	10
94	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. <i>Journal of Oncology Practice</i> , 2017, 13, e62-e67.	2.5	1
95	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 445-446.	1.4	0
96	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100.	0.7	13
97	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	0.6	47
98	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 673-674.	0.6	0
99	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1528-1534.	2.3	17
100	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. <i>Neoplasia</i> , 2016, 18, 765-774.	2.3	16
101	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	2.0	289
102	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 260-265.	1.0	0
103	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. <i>Scientific Reports</i> , 2015, 5, 10867.	1.6	87
104	A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 336-40.	0.6	2
105	Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju362-dju362.	3.0	48
106	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	1.1	88
107	Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 270-277.	0.4	35
108	Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1123-1130.	2.3	37

#	ARTICLE	IF	CITATIONS
109	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2013, 31, 450-450.	0.8	7
110	Prostate cancer incidence in males with Lynch syndrome.. Journal of Clinical Oncology, 2013, 31, 366-366.	0.8	1
111	Treatment-related hypertension (HTN) as a predictive biomarker for clinical outcomes in patients (pts) with advanced pancreas cancer (APCA) treated with bevacizumab (B): A pooled analysis of four prospective clinical trials.. Journal of Clinical Oncology, 2013, 31, 239-239.	0.8	0
112	Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 226-226.	0.8	0
113	Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS).. Journal of Clinical Oncology, 2013, 31, 514-514.	0.8	0
114	A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.. Journal of Clinical Oncology, 2012, 30, 220-220.	0.8	27
115	Retrospective analysis of treatment effects and prognostic factors associated with overall survival in patients with resected adenocarcinoma of the pancreas.. Journal of Clinical Oncology, 2012, 30, 359-359.	0.8	0
116	Phase I/II study of ⁹⁰ Y-clivatuzumab tetraxetan (⁹⁰ Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results.. Journal of Clinical Oncology, 2012, 30, 4043-4043.	0.8	0
117	Baseline albumin (b-alb) as a potential predictive biomarker for the efficacy of bevacizumab (B) therapy (tx) in patients (pts) with advanced pancreas cancer (APCA): A comparative analysis.. Journal of Clinical Oncology, 2012, 30, 4039-4039.	0.8	1
118	Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor.. Journal of Clinical Oncology, 2012, 30, e14170-e14170.	0.8	0
119	A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients (pts) with disseminated mucinous appendiceal cancers (MACA).. Journal of Clinical Oncology, 2012, 30, e14169-e14169.	0.8	0
120	Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial.. Journal of Clinical Oncology, 2012, 30, TPS10102-TPS10102.	0.8	0
121	Expanding the arsenal for metastatic colorectal cancer: a discussion of current clinical trials. Clinical Advances in Hematology and Oncology, 2009, 7, 430-2.	0.3	0